Vonicog alfa

Drug Profile

Vonicog alfa

Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; SHP-677; VEYVONDI; Vonvendi

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine
  • Developer Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Proteins; Recombinant proteins
  • Mechanism of Action Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 22 Jun 2017 The EMA validates the MAA for Vonicog alfa for the treatment of Von Willebrand's disease in European Union
  • 14 Feb 2017 Phase-III clinical trials in Von Willebrand's disease (Prevention) in Spain (IV) (EudraCT2016-001478-14)
  • 02 Dec 2016 Shire announces intention to submit expansion to marketing approval to EMA and USFDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top